Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IGMS Stock Forecast 2026-2027
$1.27
Current Price
$77.17M
Market Cap
Buy 0
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to IGMS Price Targets
-1.8%
To High Target of $1.25
-11.5%
To Median Target of $1.12
-21.3%
To Low Target of $1.00
IGMS Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-5.9%
1 Year Change
0.0%
Year-to-Date Change
-94.4%
From 52W High of $22.50
+38.0%
From 52W Low of $0.92
📊 TOP ANALYST CALLS
Did IGMS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IGM Biosciences is one of their latest high-conviction picks.
Latest IGMS Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, IGMS has a neutral consensus with a median price target of $1.12 (ranging from $1.00 to $1.25). The overall analyst rating is Buy (6.0/10). Currently trading at $1.27, the median forecast implies a -11.5% downside. This outlook is supported by 0 Buy, 3 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Asthika Goonewardene at Truist Securities, suggesting a 21.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IGMS Analyst Ratings
0
Buy
3
Hold
0
Sell
IGMS Price Target Range
Low
$1.00
Average
$1.12
High
$1.25
Current: $1.27
Latest IGMS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IGMS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2025 | Truist Securities | Asthika Goonewardene | Hold | Maintains | $1.00 |
| Jan 13, 2025 | JP Morgan | Eric Joseph | Neutral | Upgrade | $N/A |
| Jan 10, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $1.50 |
| Jan 10, 2025 | Stifel | Stephen Willey | Hold | Downgrade | $2.50 |
| Jan 10, 2025 | Truist Securities | Asthika Goonewardene | Hold | Maintains | $2.00 |
| Jan 10, 2025 | BMO Capital | Etzer Darout | Market Perform | Downgrade | $2.00 |
| Jan 10, 2025 | Jefferies | Roger Song | Hold | Downgrade | $2.00 |
| Dec 6, 2024 | BMO Capital | Etzer Darout | Outperform | Initiates | $21.00 |
| Nov 11, 2024 | Stifel | Stephen Willey | Buy | Maintains | $27.00 |
| Oct 18, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $20.00 |
| Oct 1, 2024 | Truist Securities | Asthika Goonewardene | Hold | Downgrade | $12.00 |
| Oct 1, 2024 | Wedbush | Robert Driscoll | Outperform | Maintains | $22.00 |
| Oct 1, 2024 | Guggenheim | Buy | Maintains | $20.00 | |
| Oct 1, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $17.00 |
| Oct 1, 2024 | JP Morgan | Eric Joseph | Underweight | Downgrade | $9.00 |
| Sep 5, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Maintains | $11.00 |
| Aug 23, 2024 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $24.00 |
| Aug 15, 2024 | JP Morgan | Eric Joseph | Neutral | Maintains | $12.00 |
| Aug 15, 2024 | Wedbush | Robert Driscoll | Outperform | Maintains | $25.00 |
| Aug 15, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $20.00 |
Igm Biosciences Inc. (IGMS) Competitors
The following stocks are similar to IGM Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IGMS
IGM Biosciences
mkt cap
77.17M
Igm Biosciences Inc. (IGMS) Financial Data
Igm Biosciences Inc. has a market capitalization of $77.17M with a P/E ratio of -0.4x. The company generates $145.05M in trailing twelve-month revenue with a -36.8% profit margin.
Revenue growth is +11,353.2% quarter-over-quarter, while maintaining an operating margin of +90.7% and return on equity of -47.8%.
Valuation Metrics
Market Cap
$77.17M
Enterprise Value
$-27,734,288
P/E Ratio
-0.4x
PEG Ratio
-0.5x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
+11,353.2%
Gross Margin
N/A
Operating Margin
+90.7%
Net Margin
-36.8%
EPS Growth
+11,353.2%
Financial Health
Cash/Price Ratio
+136.2%
Current Ratio
17.7x
Debt/Equity
0.0x
ROE
-47.8%
ROA
+2.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Igm Biosciences Inc. (IGMS) Business Model
About Igm Biosciences Inc.
What They Do
Develops innovative immuno-oncology therapies.
Business Model
The company develops, manufactures, and commercializes advanced immuno-oncology therapies, focusing on exclusive IgM antibodies that offer enhanced binding capabilities compared to traditional IgG antibodies. Revenue is generated through the sale of these therapies, as well as potential partnerships and collaborations within the pharmaceutical sector.
Additional Information
Igm Biosciences is headquartered in Mountain View, California, and is committed to addressing unmet medical needs in cancer treatment. The firm is engaged in pioneering antibody research, striving to improve patient outcomes through its next-generation antibody treatments designed to harness the body's immune system.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
54
CEO
Ms. Mary Beth Harler M.D.
Country
United States
IPO Year
N/A
Website
igmbio.comIgm Biosciences Inc. (IGMS) Latest News & Analysis
Latest News
Quick Summary
IGM Biosciences, Inc. (IGMS) reported Q3 earnings of $1.58 per share, surpassing the Zacks Consensus Estimate of a $0.30 loss, and improving from a loss of $0.79 per share a year prior.
Why It Matters
IGM Biosciences' unexpected earnings beat signals strong performance and growth potential, positively influencing investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IGM Biosciences has agreed to merge with Concentra Biosciences for $1.247 per share, plus a contingent value right for future cash and proceeds from certain assets.
Why It Matters
IGM Biosciences' merger with Concentra at $1.247 per share plus contingent value rights indicates a potential value unlock for shareholders, reflecting strategic positioning in biotech and possible future cash flow.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of IGM Biosciences' sale to Concentra Biosciences, which offers $1.247 per share and a contingent value right to IGM shareholders.
Why It Matters
The investigation into IGM's sale could indicate potential legal issues or undervaluation, impacting share price and investor confidence in the deal's fairness.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
IGM Biosciences, Inc. (IGMS) reported a quarterly loss of $0.86 per share, worse than the expected loss of $0.41, and a decline from a loss of $0.83 per share a year earlier.
Why It Matters
IGM Biosciences' larger-than-expected quarterly loss signals potential financial instability, which may lead to declines in investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Negative
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
1 year ago
Quick Summary
IGM Biosciences (IGMS) is anticipated to potentially exceed earnings expectations in its upcoming report, highlighting positive indicators for investors.
Why It Matters
IGM Biosciences’ potential for an earnings beat may boost investor confidence, impacting stock prices positively and attracting interest from analysts and funds.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IGM Biosciences (IGMS) is now technically oversold, suggesting reduced selling pressure, with analysts raising earnings estimates, indicating a potential trend reversal.
Why It Matters
IGM Biosciences shows signs of potential recovery as it's oversold and analysts are boosting earnings estimates, suggesting a turnaround that could attract buyers.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About IGMS Stock
What is Igm Biosciences Inc.'s (IGMS) stock forecast for 2027?
Based on our analysis of 15 Wall Street analysts, Igm Biosciences Inc. (IGMS) has a median price target of $1.12. The highest price target is $1.25 and the lowest is $1.00.
Is IGMS stock a good investment in 2027?
According to current analyst ratings, IGMS has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IGMS stock?
Wall Street analysts predict IGMS stock could reach $1.12 in the next 12 months. This represents a -11.5% decrease from the current price of $1.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Igm Biosciences Inc.'s business model?
The company develops, manufactures, and commercializes advanced immuno-oncology therapies, focusing on exclusive IgM antibodies that offer enhanced binding capabilities compared to traditional IgG antibodies. Revenue is generated through the sale of these therapies, as well as potential partnerships and collaborations within the pharmaceutical sector.
What is the highest forecasted price for IGMS Igm Biosciences Inc.?
The highest price target for IGMS is $1.25 from at , which represents a -1.8% decrease from the current price of $1.27.
What is the lowest forecasted price for IGMS Igm Biosciences Inc.?
The lowest price target for IGMS is $1.00 from Asthika Goonewardene at Truist Securities, which represents a -21.3% decrease from the current price of $1.27.
What is the overall IGMS consensus from analysts for Igm Biosciences Inc.?
The overall analyst consensus for IGMS is neutral. Out of 15 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $1.12.
How accurate are IGMS stock price projections?
Stock price projections, including those for Igm Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2026 8:07 AM UTC